SCM
REGN icon

Sigma Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Sigma Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-10,000
Closed -$3M – 86
2014
Q1 		$3M Buy
+10,000
New +$3.08M 0.15% 115
2013
Q3 		– Sell
-10,000
Closed -$2.25M – 350
2013
Q2 		$2.25M Buy
+10,000
New +$2.33M 0.1% 175

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sigma Capital Management's REGN Position: Q2 2014 in Review

Sigma Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2014, closing a stake of 10,000 shares — an estimated $3M sold.

Sigma Capital Management first reported a position in REGN in Q2 2013 and held it in 2 quarters. The position peaked at $3M in Q1 2014. 447 funds tracked by Wall St. Rank hold REGN as of Q2 2014.

  • Sigma Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Sigma Capital Management sold 10,000 Regeneron Pharmaceuticals shares in Q2 2014, an estimated $3M.
  • Sigma Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Sigma Capital Management's Regeneron Pharmaceuticals position peaked at $3M in Q1 2014.
  • 447 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.